FAFrancis Asiedu Acquah

Francis Asiedu Acquah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Francis Asiedu Acquah has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Discovery of Small Peptides as Dual Inhibitors of IL-4 and IL-13 Signaling

    by Chase Mei, Paul Atawuchugi, Tawshik Iqbal, Marc Stolyar, Marin Penner, Francis Acquah, John Fetse

    Interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling are central drivers of type 2 inflammation. While monoclonal antibodies targeting this pathway are clinically effective, their use is limited by high production cost, poor tissue penetration, increased risk of adverse effects, and parenteral administration requirement. Peptides offer advantages including structural tunability, favorable safety profiles, and improved tissue accessibility. Here, we employed an alternating phage display biopanning strategy to identify small peptides capable of dual modulation of IL-4 and IL-13 signaling. Sequential selection against IL-4 receptor α (IL-4Rα) and IL-13Rα1 enriched ligands with intrinsic dual-targeting capability. Lead peptide FMI-15 inhibited IL-4/IL-4Rα and IL-13/IL-13Rα1 interactions with IC50 values of 7.98 and 3.13 μM, respectively. In HEK-Blue reporter assays, FMI-15 suppressed IL-4- and IL-13-induced signaling with EC50 values of 25.1 and 31.6 μM, respectively. The peptide exhibited minimal cytotoxicity and moderate serum stability (t1/2 = 28.9 min). These findings establish alternating phage display as an effective strategy for identifying dual-targeting peptide modulators of cytokine signaling.

  • Open Access

    PEGASUS: Unlocking Polarity in Cell-Permeable Cyclic Peptides Using AI Models Built on Massively Parallel Biological Assays

    by Cole Baker, Francis A. Acquah, Lakshmi G. Chivukula, Liping Wu, Laurence Philippe-Venec, Mostafa Abedi, Yujun Tao, Daniel Ramírez, Matthew D. McCoy, Brandon Moore, et al.

    Cyclic peptides are a promising class of therapeutics that have the potential for oral bioavailability but are hindered by cell membrane permeability and aqueous solubility. Artificial intelligence (AI) can address the challenging multiparameter optimization of cyclic peptides, but it relies on wet lab ground truth biological data that are scarce, sparse, and dominated by hydrophobic amino acids. Here, we introduce PEGASUS, a multimodal AI model that achieves state-of-the-art performance in predicting cell membrane permeability. PEGASUS integrates an innovative high-throughput proxy biological assay (1910 PPA), which generates billions of cyclic peptides separated by permeability-related characteristics with solvent-dependent computational simulations. PEGASUS informs rules for designing cell-permeable cyclic peptides with high aqueous solubility that resemble FDA-approved therapeutics based on polarity and charge. Combining these rules with a novel generative AI, we design the first published cyclic peptides with more than two polar or ionizable fragments to achieve in vitro cell membrane permeability.


  • Open Access

    Structure-Guided Virtual Screening of Small Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy

    by Imani Roundtree, Rodney Valdivia, Angelo Altenor, Tovah St. Ignac, Alexandra Esposito, Keona Wu-Peruzzi, Genesis Fuentes, Briana Ginjauma, Francis Acquah, John Fetse

    The programmed cell death-1 (PD-1)/PD-L1 immune checkpoint plays a critical role in tumor immune evasion. While monoclonal antibodies targeting this pathway have demonstrated clinical benefit, their use is often limited by poor tumor penetration and immunogenicity. Peptides offer advantages such as tunable structures and improved tissue penetration. Here, we applied a structure-guided virtual screening strategy to identify small peptides that disrupt the PD-1/PD-L1 interaction. Alanine scanning of BMS-57 (PDB ID: 5O4Y) identified key binding residues, which informed the design of a focused virtual library of 24,423 small peptides. Top hits were selected by docking and molecular dynamics simulations. Experimental validation using ELISA and immune cell cocultures confirmed potent inhibitors. Lead peptide FJ15596 blocked PD-1/PD-L1 binding with an IC50 of 570 nM, showed 92.2 ± 1.0% inhibition at 10 μM, and restored CD3+ T cell viability in a DU145 coculture model. This strategy supports the development of small peptide scaffolds for modulating other therapeutically relevant protein–protein interactions.

  • Open Access

    Targeting RNA Structure to Inhibit Editing in Trypanosomes

    by Francis A. Acquah, Blaine H. M. Mooers

    Mitochondrial RNA editing in trypanosomes represents an attractive target for developing safer and more efficient drugs for treating infections with trypanosomes because this RNA editing pathway is not found in humans. Other workers have targeted several enzymes in this editing system, but not the RNA. Here, we target a universal domain of the RNA editing substrate, which is the U-helix formed between the oligo-U tail of the guide RNA and the target mRNA. We selected a part of the U-helix that is rich in G-U wobble base pairs as the target site for the virtual screening of 262,000 compounds. After chemoinformatic filtering of the top 5000 leads, we subjected 50 representative complexes to 50 nanoseconds of molecular dynamics simulations. We identified 15 compounds that retained stable interactions in the deep groove of the U-helix. The microscale thermophoresis binding experiments on these five compounds show low-micromolar to nanomolar binding affinities. The UV melting studies show an increase in the melting temperatures of the U-helix upon binding by each compound. These five compounds can serve as leads for drug development and as research tools to probe the role of the RNA structure in trypanosomal RNA editing.


  • Open Access

    Challenges and Proven Recommendations of Praziquantel Formulation

    by Deryl Nii Okantey Kuevi, Francis Asiedu Acquah, Amy Amuquandoh, Andrew Papa Abbey

    Background. Schistosomiasis, ranked second to malaria as one of the crucial parasitic infections in the world, infects close to 240 million people as at 2019. Praziquantel, an oral anthelmintic, is the first‐line drug for the treatment of schistosomiasis. Although the drug is safe and effective, the formulated tablets come with some limitations such as low bioavailability and bitter taste. This literature review aims to provide information on how to improve the issues of solubility, low bioavailability, and bitter taste associated with the praziquantel formulation and, subsequently, to be helpful in improving patient’s compliance. Materials and Methods. For gathering all pertinent data in this review on improving the praziquantel formulation, the following databases were used: Google Scholar, Science Direct, Scopus, PubMed, Springer Link, Elsevier, and Wiley online library. Results. Literature revealed that in improving the bioavailability of praziquantel, loading the drug with hydrogenated castor oil solid lipid nanoparticles has shown to be effective in prolonging systemic circulation from 7.6 to 95.9 hours after oral administration. Moreover, employing the solid dispersion technique using the fusion method increases the bioavailability of praziquantel about twice as much. Furthermore, incorporating a superdisintegrant or more than one disintegrant to the formulation can enhance the release of praziquantel. The addition of hydroxypropyl‐beta‐cyclodextrin (HP‐β‐CD) and sucralose as sweeteners can mask the bitter taste of praziquantel. Conclusion. The formulation approaches outlined in this review can be employed to greatly enhance the solubility, bioavailability, and taste of praziquantel. Although several techniques to improve praziquantel formulation have been widely studied, further studies on the release profile and compatibility studies with other excipients need to be investigated.


  • Open Access

    Coupling of acceptor-substituted diazo compounds and tertiary thioamides: synthesis of enamino carbonyl compounds and their pharmacological evaluation

    by Jim Secka, Arpan Pal, Francis A. Acquah, Blaine H. M. Mooers, Anand B. Karki, Dania Mahjoub, Mohamed K. Fakhr, David R. Wallace, Takuya Okada, Naoki Toyooka, et al.

    This paper describes the synthesis of enamino carbonyl compounds by the copper(I)-catalyzed coupling of acceptor-substituted diazo compounds and tertiary thioamides. We plan to use this method to synthesize indolizidine (−)-237D analogs to find α6-selective antismoking agents. Therefore, we also performed in silico α6-nAchRs binding studies of selected products. Compounds with low root-mean-square deviation values showed more favorable binding free energies. We also report preliminary pharmacokinetic data on indolizidine (−)-237D and found it to have weak activity at CYP3A4. In addition, as enamino carbonyl compounds are also known for antimicrobial properties, we screened previously reported and new enamino carbonyl compounds for antibacterial, antimicrobial, and antifungal properties. Eleven compounds showed significant antimicrobial activities.


  • Open Access

    Engineering Crystal Packing in RNA Structures I: Past and Future Strategies for Engineering RNA Packing in Crystals

    by Narsimha Pujari, Stephanie L. Saundh, Francis A. Acquah, Blaine H. M. Mooers, Adrian R. Ferré-D’amaré, Adelaine Kwun-Wai Leung

    X-ray crystallography remains a powerful method to gain atomistic insights into the catalytic and regulatory functions of RNA molecules. However, the technique requires the preparation of diffraction-quality crystals. This is often a resource- and time-consuming venture because RNA crystallization is hindered by the conformational heterogeneity of RNA, as well as the limited opportunities for stereospecific intermolecular interactions between RNA molecules. The limited success at crystallization explains in part the smaller number of RNA-only structures in the Protein Data Bank. Several approaches have been developed to aid the formation of well-ordered RNA crystals. The majority of these are construct-engineering techniques that aim to introduce crystal contacts to favor the formation of well-diffracting crystals. A typical example is the insertion of tetraloop–tetraloop receptor pairs into non-essential RNA segments to promote intermolecular association. Other methods of promoting crystallization involve chaperones and crystallization-friendly molecules that increase RNA stability and improve crystal packing. In this review, we discuss the various techniques that have been successfully used to facilitate crystal packing of RNA molecules, recent advances in construct engineering, and directions for future research in this vital aspect of RNA crystallography.


  • Open Access

    Simulations of Promising Indolizidine—α6-β2 Nicotinic Acetylcholine Receptor Complexes

    by Francis A. Acquah, Matthew Paramel, Adama Kuta, Syed R. Hussaini, David R. Wallace, Blaine H. M. Mooers

    Smoking-cessation drugs bind many off-target nicotinic acetylcholine receptors (nAChRs) and cause severe side effects if they are based on nicotine. New drugs that bind only those receptors, such as α6β2* nAChR, implicated in nicotine addiction would avoid the off-target binding. Indolizidine (-)-237D (IND (-)-237D), a bicyclic alkaloid, has been shown to block α6β2* containing nAChRs and functionally inhibit the nicotine-evoked dopamine release. To improve the affinity of indolizidine (-)-237D for α6β2*, we built a library of 2226 analogs. We screened virtually the library against a homology model of α6β2 nAChR that we derived from the recent crystal structure of α4β2 nAChR. We also screened the crystal structure of α4β2 nAChR as a control on specificity. We ranked the compounds based on their predicted free energy of binding. We selected the top eight compounds bound in their best pose and subjected the complexes to 100 ns molecular dynamics simulations to assess the stability of the complexes. All eight analogs formed stable complexes for the duration of the simulations. The results from this work highlight nine distinct analogs of IND (-)-237D with high affinity towards α6β2* nAChR. These leads can be synthesized and tested in in vitro and in vivo studies as lead candidates for drugs to treat nicotine addiction.